Merck & Co licenses Japan Tobacco's novel osteoporitic
This article was originally published in Scrip
Merck & Cohas acquired the global rights outside Japan to a novel compound for osteoporosis being developed by Japan Tobacco (JT). The move should help to shore up the US firm's franchise in this therapeutic area following the loss of exclusivity for Fosamax (alendronate) earlier this year.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.